- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Patent
- Patent Infringement
- Patent Strategy
- PM(NOC)
- Procedure
- Prosecution
- Services
- Summary
- Trade Secrets
- Trade-mark
- Use
- Validity
- 3D printing
- 6.08
- abandonment
- abstract
- abstract theorems
- accounting of profits
- acquired distinctiveness
- actions
- actual notice
- agreement
- airport security
- ambiguity
- amending
- amendment
- Amendments
- Anticipation
- application
- application chain
- arbitrary
- arbitration
- Assignment
- Australia
- bad faith
- bill
- Bill C-31
- Bill C-43
- Bill C-8
- Bill C-86
- biologics
- Biotech Patents
- book launch
- border measures
- brand
- broadcasting
- budget
- burden of proof
- calculation
- call processing
- Canada
- Canada Gazette
- canadian patent law
- causal link
- cdrp
- certificate of supplementary protection
- champerty
- chemical patent
- ciba
- CIPO
- cira
- Claim Construction
- Class Actions
- college of agents
- combination
- combination drugs
- commissioner
- Common General Knowledge
- complete code
- Confidential Information
- confidentiality
- confidentiality order
- conflict of interest
- conflicts
- conflicts of interest
- confusingly similar
- confusion
- constitution
- constitutional
- constitutionality
- contract
- contributory infringement
- Copyright
- copyright infringement
- copyright test
- Costs
- counsel
- CSP
- damages
- Data
- Data Protection
- deadlines
- defamation
- defences
- delay to market entry
- delayed market entry
- descriptive
- design patents
- designs
- deviation
- digital infringement
- disclosure
- distinctive
- distinctive feature
- distinctiveness
- diversity
- division of powers
- DNA Patents
- domain
- domain names
- dosage range
- Double Patenting
- doubtful cases
- e-commerce
- Early dismissal
- errors
- essentiality of elements
- Ethics
- Europe
- Evidence
- examination quality
- examination statistics
- expert
- expert blinding
- expert evidence
- Experts
- Expungement
- extraterritoriality
- federal court
- federal court of appeal
- fee
- fees
- file wrapper
- filing
- financial services
- foreign issue estoppel
- forum selection
- fraud
- Free World Trust
- funding
- future infringement
- generics
- geographical indications
- global
- Good Faith
- government
- grace period
- grey marketing
- Hague
- hearsay
- hearsay evidence
- Honest Contractual Performance
- human use
- ICSID
- Illegality
- Improver
- Indefiniteness
- Inducement
- industrial designs
- infringement
- inherent distinctiveness
- injunction
- Injunctions
- Innovation
- insufficiency
- insufficient disclosure
- intellectual property
- intent
- Inter Partes Review
- interlocutory injunction
- Internet
- intra vires
- invalidated
- invalidation
- inventor removal
- inventorship
- IP
- IP management
- ip regime
- IP Strategy
- IPO
- ISP
- IT patent
- ITC
- Jurisdiction
- law
- law firm
- Legal Retainer
- legal test
- legislative reform
- legitimate interest
- license
- licensee
- Licensing
- limitation periods
- litigation
- litigation evidence
- litigation funding agreement
- madrid
- maintenance
- material facts
- Methods of Medical Treatment
- minister of health
- minorities
- misleading
- monopoly
- motion
- Motion to dismiss
- Motion to strike
- NAFTA
- new act
- no chance of success
- non-infringing alternative
- non-statutory subject matter
- notice of allegation
- notice to rectify
- novelty
- obvious to try
- Obviousness
- official marks
- on-sale bar
- Online
- ontario
- opposition
- outsourcing
- Overbreadth
- overlapping
- overpromising
- ownership
- Ownership & Inventorship
- PAB
- Passing Off
- Patent
- patent act
- patent agent
- Patent Agents
- patent appeal board
- patent application
- patent book
- patent eligibility
- patent infrigement
- patent infringement
- patent law
- patent litigation
- Patent Office
- patent ownership
- patent protection
- patent rules
- Patent Strategy
- patent term adjustment
- patent trolls
- Patentable Subject Matter
- patented medicines
- patented medicines prices review board
- patentee
- patents
- PCT
- pharma
- pharmaceutical
- pharmaceutical patent
- pharmaceutical pricing
- plain and obvious
- PLT
- PM(NOC)
- PM(NOC) Damages
- PMNOC Regulations
- PMPRB
- posita
- price regulation
- prices
- prior disclosure
- prior disclosure defence
- priority
- priority claim
- priority date
- Privilege
- procedure
- Product Specificity
- profit
- Promise
- promise doctrine
- proprietor
- prosecution
- protective order
- prothonotaries
- provisional patent
- Public Servant
- Punitive Damages
- quantification
- ramped-up sales
- Records
- registration
- relevant date for construction
- remedies
- representation
- requisition
- responding
- Royalties
- s. 27
- s. 45
- s. 53
- SCOTUS
- second person
- Secondary Infringement
- secondary meaning
- section 101
- section 28
- Section 45
- section 50
- Section 52
- section 56
- section 7
- security
- selection patents
- Services
- settlement
- skilled person
- Software Copyright
- Software Patent
- software patents
- Sound Prediction
- specification
- springboard profits
- SRED
- Standard of Review
- standing
- standing to appeal
- Startups
- statute of monopolies
- statutory subject matter
- subject matter
- Sufficiency
- Summary Judgment
- summary trial
- supreme court
- surname
- swiss
- tadalafil
- TPP
- trade secrets
- trade-mark
- Trade-mark Infringement
- Trade-mark Licensing
- Trade-mark Use
- trade-marks act
- trademark
- Trademark Act
- trademark agent
- trademarks
- Trademarks use
- treaty
- UK
- United States
- unpatentable
- untrue material allegation
- US
- use
- useful article
- USMCA
- USPTO
- Utility
- validity
- variant
- Varying records
- veterinary use
- wenger
- women
February 5, 2015
February 5, 2015
AbbVie Biotechnology Ltd v Canada (Attorney General), 2014 FC 1251 - The core of the Commissioner’s argument was that Janssen Inc v Mylan Pharmaceuticals ULC, 2010 FC 1123, broadened the prohibition against patents on methods of medical treatment to include generally claims which restrict the “how and when” a physician could administer a particular drug. The Court found that the Commissioner had misread Janssen.